The United Kingdom’s National Health Service (NHS) is accelerating the rollout of its pioneering cancer vaccine trials, utilizing the same mRNA technology as the Pfizer COVID-19 vaccine. Each vaccine will be tailored to the individual patient’s genetic profile, marking a significant advancement in personalized medicine.
Patients who meet the eligibility criteria can join the trial by consenting to have their blood and tissue samples analyzed. This approach customizes each vaccine to match the DNA of the recipient, maximizing the potential for effective treatment.
Already, dozens of participants have enrolled in the Cancer Vaccine Launch Pad program, with thousands more expected to join across 30 sites in the UK. Initially, the focus is on patients with bladder, colorectal, kidney, lung, skin, and pancreatic cancers, with plans to include more cancer types as the program progresses.
Amanda Pritchard, head of NHS England, highlighted the goal of the program: “Our national matchmaking service will ensure as many eligible patients as possible get the opportunity to access these trials.”
Announced ahead of the American Society of Clinical Oncology (ASCO) conference in Chicago, the NHS program is in collaboration with German vaccine maker BioNTech. BioNTech’s success with mRNA COVID-19 vaccines has opened the door for the technology’s application to various diseases.
At the ASCO conference, BioNTech is also presenting early findings on the potential of measuring circulating tumor DNA for early detection of colorectal cancer, a disease responsible for approximately 930,000 deaths globally in 2020.
The first patient in the program, 55-year-old Elliot Pfebve, who was diagnosed with colorectal cancer during a routine check-up, has already received the world’s first mRNA cancer vaccine. Following surgery and chemotherapy, Pfebve is now part of this groundbreaking trial.
Victoria Kunene, the trial’s principal investigator, expressed optimism about the vaccine’s potential: “Based on the limited data we currently have, this could prove to be a significant and positive development for patients. However, more data is needed, and we continue to recruit suitable patients to establish this further.”
Pfebve is hopeful about his participation: “Being part of this trial has been a crucial decision in my life. After the challenges of diagnosis and chemotherapy, it’s wonderful to contribute to something that could lead to new cancer treatments. If others benefit from this trial, that’s even better.”
More on next-gen vaccines: New Vaccine Could Protect Against Any Strain of a Virus With One Shot